E-PaperSun Pharma Advanced Research Com Q3 FY24 results: loss at ₹99.65Cr, Revenue decreased by 89.43% YoY
Sun Pharma Advanced Research Com Q3 FY24 results: Revenue decreased by 89.43% YoY & loss at ₹99.65Cr
Sun Pharma Advanced Research Com declared their Q3 FY24 results on 05 Feb, 2024. The topline decreased by 89.43% & the loss came at ₹99.65cr. It is noteworthy that Sun Pharma Advanced Research Com had declared a profit of ₹10.15cr in the previous fiscal year same period.
As compared to the previous quarter, the revenue declined by 34.56%.
The Selling, general & administrative expenses rose by 2.98% q-o-q & decreased by 5.7% Y-o-Y.
The operating income was down by 11.76% q-o-q & decreased by 910.57% Y-o-Y.
The EPS is ₹-3.07 for Q3 FY24 which decreased by 977.14% Y-o-Y.
Sun Pharma Advanced Research Com has delivered -4.67% return in the last 1 week, 50.91% return in the last 6 months, and 23.26% YTD return.
Currently, Sun Pharma Advanced Research Com has a market cap of ₹11471.84 Cr and a 52wk high/low of ₹423.35 & ₹162.1 respectively.
As of 07 Feb, 2024, out of 2 analysts covering the company, 1 analyst has given a Buy rating & 1 analyst has given a Strong Buy rating.
The consensus recommendation as of 07 Feb, 2024, was to Strong Buy.
Sun Pharma Advanced Research Com Financials
| Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 13.86 | 21.18 | -34.56% | 131.09 | -89.43% |
| Selling/ General/ Admin Expenses Total | 93.51 | 90.8 | +2.98% | 99.16 | -5.7% |
| Depreciation/ Amortization | 3.16 | 3.18 | -0.63% | 3.13 | +0.96% |
| Total Operating Expense | 119.64 | 115.83 | +3.29% | 118.04 | +1.36% |
| Operating Income | -105.78 | -94.65 | -11.76% | 13.05 | -910.57% |
| Net Income Before Taxes | -99.65 | -86.42 | -15.31% | 10.15 | -1081.77% |
| Net Income | -99.65 | -86.42 | -15.31% | 10.15 | -1081.77% |
| Diluted Normalized EPS | -3.07 | -2.66 | -15.41% | 0.35 | -977.14% |
- Top Gainers
- Top Losers
- 52 Week High
